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P
ercutaneus coronary intervenions (PCI) has evolved to the mainstream revascularizaion method far outnumbering coronary artery bypass grating (CABG). However, the major drawback of PCI is a higher rate of target lesion revascularizaion (TLR) in comparison to CABG due to in-stent restenosis. Restenosis ater angioplasty has always been a signiicant problem in intervenional cardiology and is associated with signiicant morbidity and costs, with a wide spectrum of clinical presentaion. The disadvantages of balloon angioplasty has been removed when bare metal stents (BMS) were invented. The introducion of these devices significantly reduced restenosis after angioplasty. Development of drug eluing stents (DES) an another milestone in treatment of patients with coronary artery disease. The high eicacy of these devices in prevenion of restenosis compared with bare metal stents has allowed percutaneus coronary intervenion to be used in complex lesions. Introduction of DES reduced the number of target lesion revascularizaions but did not eliminate the in-stent restenosis (ISR). The populaion treated with BMS and DES is very large 1 and because of the complex subset of paients and lesions the overall rate of ISR remains significant. Although several treatment opions are available nowadays such as repeat stening, balloon angioplasty (BA), drug-coated balloons (DCB) there it is always a dilemma for intervenional cardiologist which devices to use, so management remains challenging. We provide comprehensive review of novel technique in ISR treatment: drug eluting balloons (DEBs).
Deiniion
Restenosis is deined as reducion of ≥50% of lumen diameter ater PCI at follow-up angiography. Although this deiniion was used as end point in large number of clinical trials it has to be emphasized that apart from angiographic indings clinical manifestaion of ischemia plays signiicant role in decision of treatment.
Pathophysiology
Ater stent implantaion, which damages the endothelium and leads to regional and systemic inlammatory reacion, process of neoinima proliferaion begins and in months leads to neoinimal hyperplasia 2 . Stent underexpansion or not opimal atheroscleroic plaque coverage with stent favors ISR. But according to the latest indings it seems that one more factor is responsible for ISR, especially in late stage -neoatherosclerosis 3 . What is interesing novel atheroscleroic plaques are formed faster in drug eluing stent (ater one year) than in bare metal stent (ater four years). Detailed descripion of pathophysiology of ISR is will not be the subjects of this paper. Type of ISR and cause of its occurrence determines its treatment.
Treatment
When treaing ISR we should take several possibiliies into consideraion and these are: opimal medical therapy (OMT),balloon angioplasty, stening (BMS, the same DES, diferent DES), DEB and cardiac surgery. In irst human trial on DEB -a PACCOCATH ISR I/II paients with BMS-ISR were randomized to Paccocath DEB versus standard balloon angioplasty. Ater 6 months major cardiac Srce i krvni sudovi 2014; 33(1): 41-43 events (MACE) appeared in 4% in DEB arm and 31% in BA group 4 . Ater 24 months observaion MACE rated 11% vs 46% and target lesion revascularizaion (TLR) 6% and 37% respecively in DEB and BA arm 5 . In other trial on drugcoated balloons use of DEB resulted in smaller late lumen loss (LLL) in BMS restenosis to compare with DES restenosis (-0,05 vs 0,19 mm respecively) what relected in fewer revascularizaions at one year (2.4 vs 17.1% respecively) 6 . Similarly, both the Spanish DIOR and the SeQuent Please registries 7, 8 highlighted beter clinical outcomes with BMS ISR compared to DES ISR. However, outcomes of paclitaxel versus non-paclitaxel DES ISR treated with Sequent Please did not difer (TLR: 8.3% versus 10.8%; P=0.46). Perhaps the eicacy of drug coated balloons in treaing BMS ISR relects the fact that a drug is introduced for the irst ime, whereas DCB is less eicacious in a 'drug-resistant' vessel manifesing DES ISR. Another reason could be that drug eluing stents are implanted in complex lesions which predisposes to restenosis. Comparison of drug-coated balloons with drug eluing stents (SeQuent Please, B. Braun versus TAXUS stent by Boston Scieniic) in management of in-BMS restenosis was analyzed in PEPCAD II trial which demonstrated non-inferiority. Ater 6 months of follow up late lumen loss was esimated as 0,38±0,61 mm in DES and 0,17±0,42 mm in DEB (P=0,03) and binary restenosis respectively 20% i 7% (P=0,03). Ater 12 months of observaion MACE appeared in 22% in DES and 9% in DEB group (P=0,08) 9 . In recently published German consensus on drug-coated balloon [10] authors suggest to treat BMS in-stent restenosis with drug-coated balloons leaving DES as a bailout therapy when dissecion ater predilataion appears with TIMI low < III or when residual stenosis exceeds 30%. The used DEB should extend 2-3 mm beyond the pre-dilated area, balloon/vessel raio should equal 0.8-1.0 and pressure 8-10 atm, whereas ime of inlaion must not be shorter than 30 second. The authors suggest predilataion with convenional balloon not longer than stent if ISR is restricted to stent, with diameter approximately 0.5 mm smaller than vessel diameter and with nominal pressure. Second convenional balloon should be shorter than stent with balloon to vessel diameter raio 0.8-1.0 and inlated with pressure 12-16 atm. The European guidelines give DEB class IIa and level of evidence B in bare metal stent restenosis treatment 11 . In DES ISR situaion is more complicated and there is now clear evidence what kind of management gives the best results. There is evidence that implantaion of another DES is beter than BA
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. ISAR DESIRE 2 study was designed to answer the quesion whether we should use stent eluing the same or alternaive drug. There was no diference between sirolimus eluing stent (SES) or paclitaxel eluing stent (PES) in LLL, TLR or binary restenosis 13 . In other trial, PEPCAD-DES 14 , where DEB and BA in treatment DES ISR were compared the TLR and MACE rated signiicantly lower in group of drug-coated balloon (16.7% vs 50% and 15.3% vs 36,8% respecively). The treatment with DEB resulted with signiicantly lower LLL (0.43 versus 1.03 mm) and restenosis (17.2% versus 58.1%). Finally in recent ISAR DESIRE 3 study 15 the comparison of all three methods (BA, DEB, DES) in treatment of DES in-stent restenosis was made. There was no diference between diameter stenosis between DEB and DES (38% and 37.4% respecively) and both methods were superior to BA (54.1%). In terms of binary stenosis DEB and DES were comparable (26.5% and 24.0%) and superior to BA (56.7%). As for TLR in DEB 22.1%, in DES 13.5% (P=0.09), in BA 43.5%. That led authors to conclusion that in paients presening with 'limus'-DES restenosis, DEB therapy is non-inferior to repeat stening with PES. Both DEB and PES therapy are superior to balloon angioplasty alone. It may seem counterintuiive that short balloon inlaion with DEB can be superior to DES which have a longer duraion of drug but delivery there are several theoreical advantages of DEB:
• avoiding the problem of permanent implant causing inlammaion and hypersensiivity reacion • delivery of aniproliferaive medicaion when needed, for instance immediately ater the barotraumas induced by balloon angioplasty • avoiding muliple layers of stent • avoiding the potenial risk of corrosion of the stent:
the mechanical fricion between overlapping stents and chemical reacions between dissimilar alloys if mixing diferent stent types could lead to corrosion. Stent alloys form a protecive oxide ilm, insulaing the stent struts from the corrosive body luids. There is a risk of mechanical damage of the oxide ilm caused micromoion at point of stent overlap. If this protecive ilm is geing scratched of by overlapping stent struts the underlying stent struts get exposed and may undergo corrosion.
• overlapping stents of diferent alloys could theoreically lead to galvanic corrosion. This can be avoided by DEB. However, these concerns are rather theoreical, there is no clinical evidence which indicates a problem of using diferent types of overlapping stents 16 .
Conclusion
By obviaing the need for addiional stent implantaion treatment with a drug-eluing balloon may be the treatment of choice in paients presening with 'limus'-DES restenosis. In bare metal stent restenosis the drug-coated balloon should be the golden standard therapy leaving DES implantaion only as bailout therapy. Balloon angioplasty can be successfully used when stent underexpansion diagnosed with IVUS is cause of ISR and when dealing with focal restenosis.
